November 13, 2019 — Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in FLT3-ITD-positive R/R AML in the global, randomized, phase 3 QuANTUM-R study (Cortes et al. Lancet Oncol, 2019; NCT02039726). Patients with R/R FLT3-ITD-positive AML were randomized 2:1 to receive single agent quizartinib or investigator’s choice of pre-selected SC.
Read more
November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.
Read more
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.